Erwinia chrysanthemi

-----Original Message-----
From: U.S. Food & Drug Administration (FDA)
Sent: 11/18/2011 3:38:32 PM
To: guyperea@live.com
Subject: Erwinia chrysanthemi

FDA approved asparaginase Erwinia chrysanthemi [Erwinaze, injection, EUSA Pharma (USA), Inc.] as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase. (November 18, 2011) More Information: http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm280543.htm

---

Subscriber Services:
Manage Preferences  |  Unsubscribe  |  Help with this service

Stay Connected:

---

This email was sent to guyperea@live.com using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420